@article{article, title  = {{Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2019}},

 month = {{5}},

 author = {{Hussain SA and Maroto P and Climent MÁ and Bianchini D and Jones RH and Lin C-C and Wang S-S and Dean E and Crossley K and Schlieker L and Bogenrieder T et al}},

 doi = {{10.1200/jco.2019.37.15_suppl.5030}},

 volume = {{37}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{5030-5030}},

 note = {{Accessed on 2024/12/22}}}